An Engineered Bacterium-Based Lactate Bioconsumer for Regulating Immunosuppressive Tumor Microenvironment to Potentiate Antitumor Immunity
ACS Materials Letters · 02.10.2023 · 5 (10) · 2785-2798
DOI: 10.1021/acsmaterialslett.3c00749 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Materials Letters, online erschienen am 14.09.2023. Verfasst von Shi-Man Zhang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
In this study, a bacterium-based lactate bioconsumer (designated Bac@RFH) was elaborately engineered for persistent lactate consumption to potentiate antitumor immunotherapy. Specifically, Shewanella oneidensis MR-1 was surface-modified with RFH nanoparticles (R848-loaded Fe-TCPP metal–organic framework nanoparticles coated with hyaluronic acid) via covalent borate ester bonds to prepare Bac@RFH bioconsumer, which could specifically target and colonize in tumors to efficiently metabolize intratumoral lactate and concurrently trigger the reduction of the Fe 3+ moieties of RFH through bacteria-mediated electron transfer, resulting in the decomposition of RFH to release Fe 2+ and R848. Moreover, the overexpressed H 2 O 2 in the tumor microenvironment (TME) was catalyzed by the Fe 2+ -driven Fenton reaction to produce cytotoxic ROS, which elicited immunogenic cell death of tumor cells, resulting in DCs maturation and effector T cells activation to eliminate tumors. With the combination of R848-mediated immune activation, Bac@RFH could significantly reshape the immunosuppressive TME for boosting antitumor immunity, such as reducing the recruitment of Tregs and MDSCs as well as promoting the M2-to-M1 polarization of tumor-associated macrophages. In addition, the synergy of Bac@RFH and αPD-1 could evoke robust immune responses to suppress tumor growth and achieve a tumor suppression rate over 90%, which represents a smart strategy to potentiate antitumor immunotherapy via bacterium-based metabolic regulation.
Förderung
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Zhang, S., Jin, X., Luo, G., Liang, J., Wang, Y., Wang, J., Meng, R., Lin, Y., Chen, W., & Zhang, X. (2023). An Engineered Bacterium-Based Lactate Bioconsumer for Regulating Immunosuppressive Tumor Microenvironment to Potentiate Antitumor Immunity. ACS Materials Letters, 5(10), 2785-2798. https://doi.org/10.1021/acsmaterialslett.3c00749
Vancouver
Zhang S, Jin X, Luo G, Liang J, Wang Y, Wang J, et al. An Engineered Bacterium-Based Lactate Bioconsumer for Regulating Immunosuppressive Tumor Microenvironment to Potentiate Antitumor Immunity. ACS Materials Letters. 2023;5(10):2785-2798. doi:10.1021/acsmaterialslett.3c00749
BibTeX
@article{Zhang2023,
author = {Zhang, Shi-Man and Jin, Xiao-Kang and Luo, Guo-Feng and Liang, Jun-Long and Wang, Yu-Zhang and Wang, Jia-Wei and Meng, Ran and Lin, Yan-Tong and Chen, Wei-Hai and Zhang, Xian-Zheng},
title = {An Engineered Bacterium-Based Lactate Bioconsumer for Regulating Immunosuppressive Tumor Microenvironment to Potentiate Antitumor Immunity},
journal = {ACS Materials Letters},
year = {2023},
volume = {5},
number = {10},
pages = {2785--2798},
doi = {10.1021/acsmaterialslett.3c00749}
}
EUVIMED